Overview

Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Status:
Enrolling by invitation
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment in Study URO-901-3005 (NCT03902080).
Phase:
Phase 3
Details
Lead Sponsor:
Urovant Sciences GmbH